Post-Approval watch: tracking side effects of new cancer combo
NCT ID NCT05835778
Summary
This study monitored the safety of a drug called IMFINZI when used with standard chemotherapy in 236 patients with advanced bile duct cancer that cannot be removed by surgery. It was conducted in Japan after the treatment was approved, to better understand the real-world side effects. The main goal was to track how often and what types of adverse reactions occurred during routine use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Aomori, Japan
-
Research Site
Chiba, Japan
-
Research Site
Ehime, Japan
-
Research Site
Fukushima, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Kagawa, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Miyagi, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nagasaki, Japan
-
Research Site
Nara, Japan
-
Research Site
Numakunai, Japan
-
Research Site
Okayama, Japan
-
Research Site
Osaka, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shiga, Japan
-
Research Site
Shimane, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tochigi, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Yamaguchi, Japan
Conditions
Explore the condition pages connected to this study.